Form 4: Inhibitor Therapeutics Director Niraj Vasisht Reports Stock Award and Disposal

Director Niraj Vasisht reports acquisition of 50,000 shares of restricted common stock as compensation and disposal of 150,000 shares.

Summary

• On April 1, 2025, Niraj Vasisht, a director of Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock.
• These shares were awarded as compensation under the company's 2014 Equity Incentive Plan.
• On the same day, Vasisht disposed of 150,000 shares of common stock.
• Following these transactions, Vasisht directly owns 150,000 shares of Inhibitor Therapeutics.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports routine stock transactions by a company director. The disposal of shares is balanced by the acquisition of shares as compensation.

Positives

• The acquisition of shares as compensation aligns the director's interests with those of the shareholders.

Negatives

• The disposal of 150,000 shares by the director could be interpreted negatively by the market.

Risks

• The disposal of a significant number of shares by a director could create uncertainty among investors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge sentiment and potential future performance.

Stakeholder Impact

• Shareholders may react to the director's stock disposal, potentially influencing the stock price.

Key Dates

Keywords

Inhibitor Therapeutics, Director, Niraj Vasisht, Stock, Acquisition, Disposal, Compensation, Form 4